FDA 483 - E2P4 Labs - September 17, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of E2P4 Labs, a reproductive firm in Plano, TX, revealed three observations related to deficiencies in their handling of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). The firm failed to properly document donor eligibility determinations in summaries of records and lacked adequate written procedures for record retention and for determining donor eligibility. These findings indicate significant issues with the firm's quality system and compliance with HCT/P regulations.
ID · 326c5820-5c18-4143-8fbe-294bfc48cf24